Every entrepreneur in drug discovery and development knows--or ought to know--that IP is your single most important asset. You need a firm understanding of the patents you control as well as any threats you face from competing claims or unclaimed territory. Companies in the small molecule space face particular challenges including the timing and scope of early patent filings. What's your IP position? Would you like a better understanding of the issues? On Tuesday, March 8, Caleb Bates, J.D., Ph.D. of Fish & Richardson will review key topics in small molecule IP. Join us.
Where & When
Zoom Webinar
Tuesday, March 8, 2022, 1:00 to 2:00 PM
Dr. Caleb Bates is a principal in Fish & Richardson’s Silicon Valley office. His practice focuses on intellectual property law, with emphasis on patent prosecution, strategic counseling, and worldwide patent portfolio management in the pharmaceutical and biotechnology fields. Caleb advises and counsels diverse clients, including early stage and established companies, research institutions, and venture capital and investment firms on how to best develop and leverage their IP assets. In addition to advising clients on IP strategy, Caleb has counseled clients in licensing, investor and company side due diligence, freedom-to-operate and patentability analyses, and in market clearance.